By the Top Tier Newswire AI Desk · August 25, 2026 at 10:21 AM ET · reviewed against 6 wire stories
SUMMIT THERAPEUTICS (SMMT) is up +4.95% in the latest session. Our newswire has captured 6 stories on SMMT across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why SMMT stock is up today
Summit Therapeutics shares rose 4.95% to $13.36 in early trading on August 25, 2026, driven by the publication of positive Phase III clinical trial results and an upgrade from two major analysts. The stock opened with a modest 0.5% gap up and reached a session high of $13.52 before settling near the upper end of the day’s range. The move reflects investor optimism over recent developments in the company’s pipeline and improved analyst sentiment.
What Happened
Summit Therapeutics announced the publication of primary analysis results from its global Phase III HARMONi trial, which showed that ivonescimab combined with chemotherapy significantly extended progression-free survival in patients with EGFR-mutated non-small cell lung cancer. The results were published in The Lancet Oncology, a respected medical journal, and represent a key milestone for the company’s development program.
In addition to the clinical news, two major analyst firms upgraded the stock. Bernstein raised its rating to Market Perform from Underperform and increased its price target to $11.90. SocGen also upgraded the stock to Market Perform and raised its price target. These upgrades came amid a broader shift in analyst coverage, with several firms revising their outlooks in recent days.
What The Data Shows
The stock has traded in a wide 52-week range of $12.07 to $30.05 and currently has a market capitalization of $10.5 billion. Despite the recent rally, the stock is still down 14.3% over the past eight sessions, closing at $12.73 before today’s move. The intraday session saw a volume of 1.0 million shares, which is 0.2 times the 3-month average. Recent insider transactions also showed strong confidence, with key executives including Co-CEOs Robert Duggan and Mahkam Zanganeh buying shares on June 12, 2026.
What To Watch
Summit Therapeutics has no scheduled earnings report in the near term. Investors will want to monitor the breadth of analyst coverage and whether additional firms follow suit with upgrades or further commentary on the HARMONi trial results.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SMMT · Aug 25 session (5-min) · +8.09% vs prior close · updated 8:47 PM ETAI sentiment, last 36h · averaged over 6 stories · 61/100 bullish
The headlines behind the move
Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
19d agoMarketChameleonBULLISH 73Product/PR
Ivonescimab Plus Chemotherapy Extends Progression-Free Survival in EGFR-Mutated NSCLC: Phase III HARMONi Study Results Published
August 25, 2026
Summit Therapeutics' global Phase III HARMONi trial demonstrates a significant and clinically meaningful increase in progression-free survival for EGFR-mutated NSCLC patients treated with ivonescimab plus chemotherapy after progression on EGFR TKI, according to a new publication in The Lancet Oncology. Upcoming key data presentations and regulatory dates could shape the therapy’s future prospects.
19d agoThe FlyBULLISH 63Product/PR
Summit announces publication of primary analysis results from Phase III HARMONi
19d agoInvestorsHubBULLISH 61Analyst
Summit Therapeutics Shares Rise After Bernstein SocGen Upgrade
Summit Therapeutics (NASDAQ:SMMT) shares rise after Bernstein SocGen upgrades the stock to Market Perform and raises its price target to $11.90.
19d agoInvesting.com MarketsNEUTRAL 50General
Why is Summit Therapeutics stock climbing today?
Why is Summit Therapeutics stock climbing today?
19d agoThe FlyBULLISH 56Analyst
Summit Therapeutics upgraded to Market Perform from Underperform at Bernstein
Bernstein upgrades Summit Therapeutics stock rating on valuation
Bernstein upgrades Summit Therapeutics stock rating on valuation
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →